

SUPPLEMENTARY DATA

Table 1 of the supplementary data - Comparative of HRQoL analysis of the patients with FCM infusion at three months follow-up.

| Test/Questionnaire | Basal (n = 205) | 3 months (n = 52) | P |
|--|--------------------|----------------------|------|
| EQ-5D-3L-mobility, n (%) | | | |
| I have no problems walking about | 78 (37.7) | 22 (42.3) | .842 |
| I have some problems walking about | 128 (61.8) | 30 (57.7) | .842 |
| I am confined to bed | 1 (0.5) | 0 (0) | - |
| EQ-5D-3L-self-care, n (%) | | | |
| I have no problems with self-care | 150 (72.1) | 40 (76.9) | .274 |
| I have some problems washing or dressing myself | 50 (24.0) | 12 (23.1) | .651 |
| I am unable to wash or dress myself | 8 (3.8) | 0 (0) | .079 |
| EQ-5D-3L-activities, n (%) | | | |
| I have no problems with performing my usual activities | 99 (47.8) | 23 (44.2) | .843 |
| I have some problems with performing my usual activities | 94 (45.4) | 28 (53.8) | .844 |
| I am unable to perform my usual activities | 14 (6.8) | 1 (1.9) | .308 |
| EQ-5D-3L-pain, n (%) | | | |
| I have no pain or discomfort | 85 (40.9) | 19 (36.5) | .839 |
| I have moderate pain or discomfort | 103 (49.5) | 28 (53.8) | .990 |
| I have extreme pain or discomfort | 20 (9.6) | 5 (9.6) | .727 |
| EQ-5D-3L-anxiety, n (%) | | | |
| I am not anxious or depressed | 113 (54.6) | 34 (65.4) | .420 |
| I am moderately anxious or depressed | 86 (41.5) | 16 (30.8) | .410 |
| I am extremely anxious or depressed | 8 (3.9) | 2 (3.8) | .990 |
| | | | |
| Minnesota Questionnaire | | | |
| Q1. Causing swelling in your ankles or legs? | 1.53 ±1.62 | 1.33 ± 1.39 | .569 |
| Q2. Making you sit or lie down to rest during the day? | 1.96 ±1.67 | 1.88 ± 1.49 | .646 |
| Q3. Making your walking about or climbing stairs difficult? | 2.93 ±1.69 | 2.47 ± 1.78 | .179 |
| Q4. Making your working around the house or yard difficult? | 2.41 ±1.82 | 2.06 ± 1.87 | .467 |
| Q5. Making your going places away from home difficult? | 2.60 ± 1.83 | 2.35 ± 2.02 | .258 |
| Q6. Making your sleeping well at night difficult? | 1.98 ±1.68 | 1.42 ± 1.75 | .113 |
| Q7. Making you relating to or doing things with friends or family difficult? | 1.32 ±1.56 | 1.21 ± 1.56 | .999 |
| Q8. Making you working to earn a living difficult? | 1.58 ±1.97 | 1.23 ± 1.69 | .544 |
| Q9. Making your recreational pastimes, sports, or hobbies difficult? | 1.96 ±1.95 | 1.47 ± 1.68 | .550 |
| Q10. Making your sexual activities difficult? | 1.68 ±1.92 | 1.69 ± 1.92 | .327 |

| | | | |
|---|----------------|-------------|------|
| Q11. Making you eat less of the foods you like? | 2.03 ±1.76 | 1.79 ±1.89 | .634 |
| Q12. Making you short of breath? | 2.19 ±1.75 | 1.74 ±1.73 | .885 |
| Q13. Making you tired, fatigued, or low on energy? | 2.51 ±1.74 | 1.69 ±1.94 | .165 |
| Q14. Making your stay in a hospital? | 1.30 ±1.67 | 0.92 ±1.53 | .177 |
| Q15. Costing you money for medical care? | 1.32 ±1.67 | 0.96 ±1.43 | .061 |
| Q16. Giving you side effects from treatments? | 1.00 ±1.45 | 0.96 ±1.48 | .339 |
| Q17. Making you feel you are a burden to your family or friends? | 1.25 ±1.66 | 1.29 ±1.66 | .659 |
| Q18. Making you feel a loss of self-control in your life? | 1.48 ± 1.76 | 1.45 ±1.74 | .924 |
| Q19. Making you worry? | 2.01 ±1.80 | 1.62 ± 1.80 | .172 |
| Q20. Making it difficult for you to concentrate or remember things? | 1.78 ±1.71 | 1.45 ±1.61 | .334 |
| Q21. Making you feel depressed? | 1.66 ±1.70 | 1.27 ±1.48 | .103 |
| | | | |
| MLHFQ Questionnaire | | | |
| Physical dimension | 18.4 ±10.8 | 15.9 ±10.5 | .326 |
| Emotional dimension | 8.1 ±7.3 | 7.1 ±7.0 | .318 |
| Global score | 38.4 ± 26.0 | 34.9 ±25.2 | .334 |

FCM, ferric carboxymaltose; HRQoL, health-related quality of life; MLHFQ,

Minnesota Living with Heart Failure Questionnaire; Q, question number.

There were 31 patients with incomplete basal EQ-5D-3L and Minnesota test and 147 in the 3 months follow-up.

Data are expressed as no. (%) or mean ± standard deviation.

Table 2 of the supplementary data - Comparative of the characteristics of the patients at three months according to TSAT level.

| Characteristics | TSAT < 20 (n = 184) | | | TSAT ≥ 20 (n = 34) | | | P |
|-------------------------|------------------------|-----------------|-------|-----------------------|-----------------|-------|-------|
| | Basal | 3 months | P | Basal | 3 months | P | |
| Age (years) | 73.2 (10.6) | | | 75.4 (11.6) | | | .265 |
| Sex (female), n (%) | 96 (52.2) | | | 18 (52.9) | | | .934 |
| SBP (mmHg) | 124.4 (18.9) | | | 126.4 (17.0) | | | .561 |
| HR (bpm) | 69.5 (11.9) | | | 67.1 (11.8) | | | .279 |
| Functional class, n (%) | | | | | | | .101 |
| NYHA I | 4 (2.2) | 10 (10.0) | .045 | 3 (9.1) | 20 (16.3) | .001 | |
| NYHA II | 141 (79.2) | 76 (76.0) | | 26 (78.8) | 95 (77.2) | | |
| NYHA III | 33 (18.5) | 14 (14.0) | | 4 (14.6) | 8 (6.5) | | |
| NYHA improvement ≥1 | | 40 (22.5) | | | 5 (15.2) | | .641 |
| NYHA no improvement | | 133 (74.7) | | | 27 (81.8) | | |
| NYHA deterioration ≥ 1 | | 5 (2.8) | | | 1 (3.0) | | |
| LVEF (%) | 44.4 (15.0) | | | 43.7 (15.7) | | | .805 |
| FCM dose (mg) | 951.1 (148.9) | | | 911.8 (193.5) | | | .180 |
| Theoretical dose, n (%) | 82 (44.6) | | | 18 (54.5) | | | .290 |
| Hb (g/dL) | 12.3 (1.5) | 12.9 (1.7) | .0001 | 13.1 (1.4) | 13.5 (1.1) | .018 | .013 |
| Anemia- n (%) | 84 (45.7) | | | 10 (30.3) | | | .101 |
| MCHC (pg) | 28.9 (2.8) | 30.3 (2.0) | .0001 | 30.8 (1.8) | 31.7 (1.8) | .012 | .0001 |
| MCV (fL) | 90.1 (7.9) | 94.2 (5.4) | .0001 | 93.2 (12.5) | 98.7 (5.3) | .002 | .064 |
| Serum Fe (mcg/dL) | 47.1 (16.2) | 79.9 (31.8) | .0001 | 89.8 (21.1) | 90.8 (23.9) | .845 | .0001 |
| Transferrin (mg/dL) | 284.5 (60.8) | 232.3 (50.1) | .0001 | 248.9 (41.5) | 210.6 (40.0) | .0001 | .001 |
| Ferritin (ng/mL) | 64.9 (79.3) | 280.1 (393.2) | .0001 | 108.5 (122.3) | 278.8 (124.7) | .0001 | .008 |
| TSAT (%) | 11.9 (4.1) | 24.0 (11.1) | .0001 | 25.8 (6.4) | 29.4 (9.6) | .021 | .0001 |
| Absolute ID, n (%) | 151 (82.1) | 27 (19.4) | .0001 | 23 (67.6) | 1 (4.2) | .0001 | .001 |
| NT-proBNP (pg/mL) | 4754.0 (6577.4) | 3282.4 (3611.8) | .001 | 3585.4 (4796.3) | 2452.2 (2793.7) | .122 | .285 |
| Creatinine (mg/dL) | 1.3 (0.5) | 1.3 (0.4) | .334 | 1.3 (0.6) | 1.3 (0.6) | .955 | .881 |
| eGFR (mL/min) | 58.5 (23.2) | 56.8 (20.9) | .549 | 54.4 (21.9) | 59.7 (24.7) | .746 | .367 |

BMI, body mass index; BPM, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular filtrated rate; FCM, ferric carboxymaltose; Fe, Iron; Hb, hemoglobin; HR, heart rate; ID, iron deficiency; LVEF, left ventricular ejection fraction; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood pressure; TSAT, transferrin saturation.

18 patients were excluded from the analysis for incomplete data.

The correct dose was defined according to weight and Hb³. Functional ID was defined as ferritin < 100³.